SCI Ventures
Venture capitalLondon · Seed–Series B · 18 people tracked
Investment thesis
SCI Ventures is a dedicated venture fund focused on accelerating cures and treatments for paralysis, starting with spinal-cord injury and related markets. Backed by leading paralysis research foundations and clinical centers, the fund brings together investors, entrepreneurs, clinicians and neuroscientists. It invests globally in early-stage companies — typically Seed through Series B — that are built around rigorous, innovative scientific advancements with the greatest potential to impact people living with spinal cord injury. Its aim is to move therapies from the lab to the clinic faster, catalyzing both symptomatic and curative treatments for neurological conditions.
Source: firm website, verified Aug 3, 2026.
Team · 18 people
from the firm's website & public directories
What they invest in
from 4 of 13 portfolio companiesBiotech ×3Healthtech ×3Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1Digital Health ×1
HQs:United States×2United Kingdom×1
Investments · 13 tracked
founders shown can be your intro pathNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair.
BiotechDeep TechHealthtechMedical Devices
Randall Kaye(Director)William Adams(Executive Officer)Brian Bayley(Director)Michael Abrams(Director)Paul Brennan(Director, Executive Officer)Bill Radvak(Director)
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Executive Officer, Director)
BoardCorey . Goodman(Director)Jonathan Leff(Director)Raymond J. Kelleher(Director)
Developing targeted gene therapy platform for specific neuronal populations, with initial focus on neurogenic detrusor overactivity in spinal cord injury and neurodegenerative diseases.
Leader in spinal cord stimulation technology using targeted programmed stimulation to restore movement and function, with first FDA approval expected in 2024.
HealthtechNew York, US
Benjamin Rapoport(President, Chief Science Officer)Michael Mager(Chief Executive Officer)Craig Mermel(President and Chief Product Officer)MIchael Kaswan(Chief Financial Officer)
BoardEric M. Attias(Director)Howard Morgan(Director)
Exits · 1
IPOs and acquisitions across the tracked portfolioNervGen PharmaNASDAQ: NGEN
Frequently asked questions
- What stage does SCI Ventures invest at?
- SCI Ventures invests at the Seed, Series A, Series B stages.
- What sectors does SCI Ventures focus on?
- SCI Ventures focuses on Biotech, Deep Tech, Healthtech, Impact & Social Good, Medical Devices.
- Where is SCI Ventures located?
- SCI Ventures is headquartered in London, GB.
Images
Similar investors
Innovestor is a Nordic investment group operating across venture capital, life science, real estate, energy storage, and corporate venturing platforms, and is among the most active early-stage investors in the region.
Voima Ventures is a deep tech venture capital firm that backs founders building global solutions across people, planet, and industry, from technology spin-offs to scaling companies.
Asabys Partners is a healthcare and life sciences venture capital firm that invests in innovative science and medical technologies to improve patients' lives.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Serendipity Impact VC is an early-stage venture firm backing founders building breakthrough technologies for mental and neuro health, with roots in the Israeli innovation ecosystem and a focus on the U.S. market.